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Abstract
Background: Our previous study revealed that administration of syngeneic female BALB/c mice with excessive self activated
lymphocyte-derived DNA (ALD-DNA) could induce systemic lupus erythematosus (SLE) disease, indicating that overload of
self-DNA might exceed normal clearance ability and comprise the major source of autoantigens in lupus mice. Serum
amyloid P component (SAP), an acute-phase serum protein with binding reactivity to DNA in mice, was proved to promote
the clearance of free DNA and prevent mice against self-antigen induced autoimmune response. It is reasonable to
hypothesize that SAP treatment might contribute to alleviation of SLE disease, whereas its role in ALD-DNA-induced lupus
nephritis is not fully understood.
Methodology/Principal Findings: The ratios of SAP to DNA significantly decreased and were negatively correlated with the
titers of anti-dsDNA antibodies in ALD-DNA-induced lupus mice, indicating SAP was relatively insufficient in lupus mice.
Herein a pcDNA3-SAP plasmid (pSAP) was genetically constructed and intramuscularly injected into BALB/c mice. It was
found that SAP protein purified from the serum of pSAP-treated mice bound efficiently to ALD-DNA and inhibited ALD-
DNA-mediated innate immune response in vitro. Treatment of ALD-DNA-induced lupus mice with pSAP in the early stage of
SLE disease with the onset of proteinuria reversed lupus nephritis via decreasing anti-dsDNA autoantibody production and
immune complex (IC) deposition. Further administration of pSAP in the late stage of SLE disease that had established lupus
nephritis alleviated proteinuria and ameliorated lupus nephritis. This therapeutic effect of SAP was not only attributable to
the decreased levels of anti-dsDNA autoantibodies, but also associated with the decreased infiltration of lymphocytes and
the reduced production of inflammatory markers.
Conclusion/Significance: These results suggest that SAP administration could effectively alleviated lupus nephritis via
modulating anti-dsDNA antibody production and the inflammation followed IC deposition, and SAP-based intervening
strategy may provide new approaches for treating SLE disease.
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Introduction
Defect in clearance of self nuclear antigen is the hallmark of
systemic lupus erythematosus (SLE), an autoantibody-mediated
chronic autoimmune disease characterized by the deposition of
immune complexes and its followed inflammation that contribute to
sever organ damage [1–3]. However, the precise means by which
clearance of self antigen isinefficientinSLEremain obscure. Studiesof
both mice and humans suggest that SLE could arise from excessive
production of self antigen released from unremoved apoptotic cells and
impairment in the ability of macrophages to clear self antigen [4,5].
Our previous study revealed that the syngeneic female BALB/c
mice immunized with activated lymphocyte-derived DNA (ALD-
DNA) develop high titers of anti-dsDNA antibodies, immune
complex (IC) deposition, proteinuria, and glomerular nephritis
which closely resemble human SLE [6–8], thus being used as a
model to investigate pathogenesis and potential new therapies for
human disease. These findings indicate that ALD-DNA, which
mimics large amount of self-DNA released from unremoved
apoptotic lymphocytes in SLE patients, might serve as an
important self-immunogen to trigger the autoimmune responses
which eventually lead to the pathogenesis of SLE in the murine
model.
In addition to DNA overload in SLE, insufficiency of DNA
clearance represents the other side of the coin [4]. Emerging
studies reveal that serum amyloid P component (SAP) would be
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22659one of the candidates responsible for DNA clearance [2,4]. SAP is
a member of the pentraxin family of proteins and an acute phase
reactant, which is produced primarily in the liver in response to
infection, inflammation, and trauma [9]. SAP could recognize
DNA and other ligands, activate complement, and facilitate
pathogen and nuclear antigen phagocytosis, hence playing a
nonredundant role in protection against autoimmune disease and
in resistance against selected pathogens [10]. Furthermore, SAP
shares many properties in common with IgG, including the
capacity to interact with FccR and the ability to bind to ligands
[11,12]. The interaction of SAP with FccR mediates several
functions that are analogous or opposite to those of IgG, including
modulation the response to inflammatory stimuli and opsonization
of bacteria and altered or exposed self-molecules on damages cells
[4,11], thus could compete with antibody and be used to treat
antibody-mediated disease such as SLE.
As the major DNA- and chromatin-binding protein in plasma of
mice, SAP could bind to nuclear antigens that are the target of the
autoantibodies of patients with SLE, as well as to damaged
membranes and microbial antigens [13,14]. Furthermore, SAP2/
2 mice spontaneously developed antinuclear autoimmunity and
sever glomerulonephritis, a phenotype resembling human SLE
[15], which strongly supported a role for SAP in the protection
against self-DNA and chromatin-induced autoimmunity.
Although the pathological relevance of SAP to autoimmune
disease and the significance of self-DNA in the pathogenesis of
SLE attracted much attention in recent years, whether SAP takes
responsibility for self-DNA clearance and plays a protective role in
self-DNA-induced SLE in a mouse model with clear genetic
background remain poorly understood. In the present study, we
tested the ratios of SAP to DNA and found that they decreased in
ALD-DNA-induced lupus mice as compared to controls, and were
negatively correlated with SLE disease. Further SAP gene
administration in the early stage of SLE disease could reversed
lupus nephritis via reduced pathogenic anti-dsDNA antibody
production, while in the late stage of disease, SAP gene treatment
alleviated proteuria and lupus nephritis via reducing the
infiltration of leukocytes and the production of inflammatory
markers besides decreasing the levels of anti-dsDNA antibodies.
These results indicated that SAP administration would ameliorate
self-DNA-induced lupus nephritis via regulating pathogenic anti-
dsDNA antibody production and inflammation in lupus mice,
which might provide SAP as a potential therapeutic strategy for
self-antigen induced SLE and other autoimmune disease.
Results
ALD-DNA immunization induces SLE syndrome in
non-autoimmune-prone mice
Levels of serum anti-dsDNA antibodies, which represent a
serological hallmark of SLE, tend to reflect disease severity for
SLE patients [1]. According to our previously reported procedure,
SLE murine model was generated by immunizing female BALB/c
mice with ALD-DNA (Fig. 1A) [6,7]. Compared with PBS or
unactivated lymphocyte-derived DNA (UnALD-DNA) injection,
ALD-DNA immunization generated higher levels of anti-dsDNA
IgG antibody (Fig. 1B), which was evident from week 4 and
reached the maximum at week 8 after initial injection (Fig. 1B).
Glomerulonephritis was also confirmed by urine protein quanti-
fication, H&E staining of renal tissues, and immune complex
deposition assay (Fig. 1C–G). Remarkably up-regulated urine
protein (Fig. 1C), notable glomerulonephritis (Fig. 1D and E), and
increased IgG deposition (Fig. 1F and G) were found in ALD-
DNA-immunized lupus mice as compared to PBS- or UnALD-
DNA-treated controls (Fig. 1C–G). These results demonstrate that
SLE murine model could be established through ALD-DNA
immunization.
The ratios of SAP to DNA decrease in lupus mice and are
negatively correlated with SLE disease
To study whether SAP has a correlation to SLE disease, the
levels of SAP and circulating DNA in the serum of lupus mice
generated by ALD-DNA immunization were assayed. Slightly
increased serum SAP levels accompanied with remarkably
enhanced circulating DNA levels were found in lupus mice as
compared with those in controls (Fig. 2A–D). Pearson correlation
analysis showed that the serum SAP levels were closely correlated
to the circulating DNA levels (Fig. 2E). However, the ratios of SAP
to DNA were lower in lupus mice than in controls, which
suggested that SAP protein were relatively insufficient in lupus
mice (Fig. 2F). Notably, the ratios of SAP to DNA were negatively
correlated with the levels of anti-dsDNA antibodies in SLE mice
(Fig. 2G). Taken together, these results indicate that SAP was
relatively insufficient in lupus mice.
Efficiently expressed SAP protein could inhibit
ALD-DNA-mediated innate immune responses in vitro
Our results described above provided the basis for the
hypothesis that SAP administration in vivo may modulate the
immune response in SLE disease. Consequently, pcDNA3-SAP
recombinant (pSAP) was constructed for expression of SAP. As
shown in Fig. 3A, ELISA analysis for the expression of SAP in
culture supernatants of NIH3T3 cell line transfected with pSAP
shown that SAP cDNA cloned into pcDNA3 could be correctly
transcripted, translated and the protein could be efficiently
secreted. To detect the expression of SAP in vivo, BALB/c mice
were injected intramuscularly with pSAP (100 mg/mice). Immu-
nohistochemistry examination showed an obvious expression of
SAP in the muscle received pSAP compared with that receiving
pcDNA3 (Fig. 3B). Consistently, quantitative analysis of SAP levels
in serum of mice revealed that SAP reached maximal levels at day
10 after injection and then declined (Fig. 3C). 21 days after
plasmid injection, the concentration of serum SAP protein went
back to the baseline level (Fig. 3C). In contrast, the levels of serum
SAP protein in the mice treated with parental plasmid pcDNA3 or
physiological saline were not significantly increased over the
course of the experiments (Fig. 3C). To further confirm the
expression of SAP in vivo, serum was collected on day10 after pSAP
injection and subjected to western blot analysis using specific anti-
SAP antibody. Marked immune-reactive bands were observed in
the serum from mice receiving pSAP injection (Fig. 3D), indicating
that SAP could be efficiently expressed in vivo. Accumulating data
indicate that SAP has the capacity of binding to DNA under
physiological conditions [9]. To explore the biological function of
SAP purified from the serum of mice receiving pSAP injection, the
binding ability of the purified SAP protein to ALD-DNA was
evaluated. It was found that the purified SAP protein had the
capacity to bind to ALD-DNA (Fig. 3E). Previous studies have
shown that SAP can bind macrophage and opsonize the ligands
for phagocytosis [11,16]. In order to investigate whether the
binding of SAP to ALD-DNA had any effects on the uptake of
ALD-DNA by macrophages, we performed flow cytometry to
determine the uptake of ALD-DNA or the complexes of purified
SAP protein and ALD-DNA (SAP plus ALD-DNA). However, the
intracellular DNA did not increase in macrophages in the presence
of SAP (Fig. 3F). As endocytic naked DNA was always degraded
rapidly by endosomal nucleases, we used chloroquine to prevent
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22659Figure 1. ALD-DNA immunization induces high levels of anti-dsDNA antibody and lupus nephritis. (A) Schematic diagram of animal
immunization. 6- to 8-week old female BALB/c mice were immunized subcutaneously with ALD-DNA (50 mg/mice) plus CFA at week 0, followed by
two booster immunizations of ALD-DNA (50 mg/mice) emulsified with IFA at week 2 and week 4 after initial immunization. (B) Serum anti-dsDNA IgG
levels were measured by ELISA every 2 weeks after initial immunization. Data are means 6 SD from 10 mice in each group. (C) Urine protein levels of
the mice were assessed by BCA Protein Assay Kit every 2 weeks. Data are means 6 SD from 10 mice in each group. (D) 8 weeks after initial
immunization, nephritic pathology was evaluated by H&E staining of renal tissues. Imagines (magnification6200) are representative of at least 10
mice in each group. (E) The kidney score was assessed using paraffin sections stained with H&E in (D). ***, p,0.001. (F) Glomerular immune
deposition were detected by direct immunofluorescence for IgG in frozen kidney section from ALD-DNA-immunized lupus mice or control mice.
Representative images (magnification6200) of 10 mice are shown for each group. (G) Mean glomerular fluorescence intensity (arbitrary units) was
determined for IgG in ALD-DNA-immunized lupus mice (n=10) and control mice (n=10). ***, p,0.001.
doi:10.1371/journal.pone.0022659.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22659Figure 2. The ratios of SAP to DNA decrease in SLE murine model. 6-week-old female BALB/c mice were immunized subcutaneously with
ALD-DNA, UnALD-DNA, or PBS (n=15) for 3 times in 4 weeks. (A) The dynamics of SAP level in serum of mice immunized with ALD-DNA, UnALD-DNA,
or PBS were determined by ELISA assay every 2 weeks. (B) The dynamics of circulating DNA level in serum of mice immunized with ALD-DNA, UnALD-
DNA, or PBS were determined using a PicoGreen DNA detection kit (Invitrogen) every 2 weeks. (C) SAP levels in the serum of SLE murine model and
controls were tested by ELISA at week 8 after initial immunization. n=15. (D) Circulating DNA levels in the serum of SLE murine model and controls
were determined using a PicoGreen DNA detection kit at week 8 after initial immunization. n=15. (E) The correlation between SAP and DNA levels in
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22659endosome acidification. It was found that SAP increased the
intracellular fluorescence rates of treated macrophages, indicating
that SAP binding to ALD-DNA promoted the uptake of ALD-
DNA by macrophages (Fig. 3F). Furthermore, we performed real-
time PCR to detect cytokine expression in the macrophages
cultured with ALD-DNA or the complexes of purified SAP protein
and ALD-DNA (SAP plus ALD-DNA), and found that mRNA
levels of inflammatory cytokines including TNF-a, IL-1b, IL-6, IL-
12, and MCP-1 were notably decreased in the macrophages
cultured with SAP plus ALD-DNA; however, mRNA level of IL-
10 was significantly increased in the macrophages cultured with
SAP plus ALD-DNA as compared with those of macrophages
cultured with ALD-DNA alone (Fig. 3G). These data suggest that
pSAP plasmid could be correctly transcripted, translated and the
expressed SAP protein could inhibit ALD-DNA-mediated innate
immune responses in vitro.
pSAP treatment in the early stage of SLE disease reverses
lupus nephritis via reducing anti-dsDNA antibody
production and IC deposition
To evaluate the effect of pSAP treatment in mice, ALD-DNA-
induced lupus mice with the onset of proteinuria (at week 4 after
the initial ALD-DNA immunization) were treated with pSAP
(ALD-DNA plus pSAP group). Significantly increased serum SAP
levels accompanied with remarkably decreased circulating DNA
levels were found in pSAP-treated lupus mice as compared with
those in pcDNA3-treated lupus mice (Fig. 4A and B). The ratios of
SAP to DNA were simultaneously increased in pSAP-treated lupus
mice as compared with those in pcDNA3-treated lupus mice,
which suggested that pSAP injection could reverse the insufficien-
cy of SAP in lupus mice (Fig. 4C). 12 weeks after the initial ALD-
DNA immunization, the levels of anti-dsDNA autoantibodies, IC
deposition, proteinuria, renal pathology, and kidney score were
analyzed. Notably reduced the levels of anti-dsDNA autoantibod-
ies (Fig. 4D and E), urine protein (Fig. 4F), IC deposition (Fig. 4G
and H), renal pathology (Fig. 4I), and kidney score (Fig. 4J) were
found in the pSAP-treated lupus mice as compared with those of
pcDNA3-treated lupus mice. These results show that pSAP
treatment in the early stage of SLE disease could reverse lupus
nephritis via decreasing anti-dsDNA antibody production and IC
deposition in lupus mice.
pSAP administration in the late stage of SLE disease
alleviates lupus nephritis via reducing leukocyte
infiltration and inflammatory marker production
To further evaluate the protective effect of pSAP treatment in
mice in the late stage of SLE disease, ALD-DNA-induced lupus
mice with the established lupus nephritis (at week 8 after the initial
ALD-DNA immunization) were treated with pSAP (ALD-DNA
plus pSAP group). Significantly increased serum SAP levels
accompanied with remarkably decreased circulating DNA levels
were found in pSAP-treated lupus mice as compared with those in
pcDNA3-treated lupus mice (Fig. 5A and B). The ratios of SAP to
DNA were simultaneously increased in pSAP-treated lupus mice
as compared with those in pcDNA3-treated lupus mice, which
suggested that pSAP injection could partly improve the insuffi-
ciency of SAP in lupus mice (Fig. 5C). 12 weeks after the initial
ALD-DNA immunization, the levels of anti-dsDNA autoantibod-
ies, IC deposition, proteinuria, renal pathology, and kidney score
were analyzed in the lupus murine model receiving pSAP injection
at week 8 after the initial ALD-DNA immunization when lupus
mice already had the highest levels of anti-dsDNA autoantibodies
and established lupus nephritis (ALD-DNA plus pSAP group).
Twelve weeks after the initial immunization, notably decreased
levels of urine protein (Fig. 5F) and ameliorated glomerulonephri-
tis (Fig. 5I and J) but slowly reduced levels of autoantibody titers
(Fig. 5D and E) and IC deposition (Fig. 5G and H) were found in
pSAP-treated lupus mice as compared with pcDNA3-treated lupus
mice, indicating the improved lupus nephritis was not exclusively
ascribed to the decreased anti-dsDNA antibody levels and IC
deposition.
Other than the pathogenic anti-dsDNA autoantibody produc-
tion and IC deposition, severe renal injury can be mediated by
infiltrating proinflammatory leukocyte populations [17]. Flow
cytometry analysis of cells extracted from kidneys of lupus mice
showed a marked decrease in the number of CD45
+ leukocytes in
kidneys isolated from pSAP-treated lupus mice as compared with
pcDNA3-treated lupus mice (Fig. 6A). Further flow cytometry
analysis of infiltrating leukocyte populations revealed that pSAP-
treated lupus mice displayed a decrease in renal T cells (CD4
+) and
B cells (CD19
+) as compared to pcDNA3 treated lupus mice
(Fig. 6A), but T and B cells only account for a portion of the
decreased infiltrating cells in the kidneys of pSAP-treated lupus
mice. Flow cytometry analysis of the presence of myeloid cells
showed that pSAP-treated lupus mice exhibited a notable decrease
in the number of F4/80
+ macrophages (Fig. 6A), but there was no
significant decrease in the number of CD11c
+ dendritic cells (data
not shown), suggesting that macrophages were the key cells that
was influenced by pSAP treatment. As a set of inflammatory
markers mainly secreted by macrophages were expressed in
kidneys following glomerular immune complex deposition
[8,18,19], further studies using ELISA analysis allowed us to
determine several key markers in kidneys of mice. It was found
that TNF-a, IL-1b, IL-6, IL-12 and MCP-1, which were
upregulated in kidneys of ALD-DNA-induced lupus mice, were
decreased in the pSAP-treated lupus mice (Fig. 6B). However,
levels of IL-10 were notably increased in the pSAP-treated lupus
mice (Fig. 6B). Analysis of the cytokine profile in serum of mice
further confirmed that the inflammatory markers (including TNF-
a, IL-1b, IL-6, IL-12, and MCP-1) were extensively and
dramatically decreased in pSAP-treated lupus mice as compared
with other control groups (Fig. 6C). These data suggest that pSAP
treatment in the late stage of SLE disease could ameliorate the
lupus nephritis via reducing the number of infiltrating inflamma-
tory cells and decreasing the levels of inflammatory markers.
Discussion
We have provided here evidence that relative insufficiency of SAP
played a critical role in the pathological process of the ALD-DNA-
induced lupus nephritis,and verified that administrationofSAPinvivo
by a plasmid encoding the SAP, could significantly ameliorated the
severity of SLE disease, as demonstrated by decreased levels of anti-
dsDNA antibodies, reduced immune complex deposition, less
proteinuria, less lupus nephritis, and decreased kidney score of
ALD-DNA-immunized lupus mice. n=15. Pearson correlation analysis was used to carry out the correlation study. r=0.76; P,0.05. (F) The ratios of
SAP to DNA in SLE murine model and controls. Data are means 6 SD from 15 mice in each group. ***, P,0.001. (G) The correlation between the ratio
of SAP to DNA and anti-dsDNA IgG level in SLE murine model. Pearson correlation analysis was used to carry out the correlation study. r=0.90;
P,0.001.
doi:10.1371/journal.pone.0022659.g002
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22659glomerulonephritis. This therapeutic effect was closely associated
with reduced production of anti-dsDNA antibodies in the early stage
of the disease and significantly decreased infiltrating lymphocytes and
reduced levels of inflammatory markers in kidneys of pSAP-treated
mice in the late stage of the disease.
In previous study, the crucial and versatile functions of SAP in
autoimmune disease have been well established [9,10]. SAP
2/2
mice spontaneously develop antinuclear autoimmunity and severe
glomerulonephritis, a phenotype resembling human SLE [15].
However, people doubt if SAP deficiency or strain combination
Figure 3. Efficiently expressed SAP could inhibit ALD-DNA-induced innate immune response. (A) NIH 3T3 cells were transfected with
pcDNA3 or pcDNA3-SAP plasmid (pSAP) using Lipofectamine 2000 transfection reagent, and cell supernatants were collected and subjected to ELISA
assay for the expression of SAP protein at 24 h, 48 h, and 72 h post transfection. Data are means 6 SD of three independent experiments. (B–D) 6-
week-old female BALB/c mice were injected intramuscularly with pSAP (100 mg/mice). (B) Immunohistochemistry examination was performed to
determine the expression of SAP protein with anti-mouse SAP Ab in the muscle received pSAP injection. Imagines (6400) are representative of at
least 10 mice in each group. (C) ELISA assay was performed to determine the levels of SAP protein in the serum of mice received pSAP injection. Data
are means 6 SD of three independent experiments. n=10. (D) The serum was collected on day 10 after pSAP injection. Western blot analysis was
performed to detect the expression of SAP in serum of mice received pSAP injection. Data are representative of at least 10 mice in each group. (E–G)
SAP protein was purified from the serum of mice received pSAP injection. (E) The binding ability of the purified mouse SAP protein to DNA was
detected by dot blot analysis. Quantitative analysis of blots was reflected as mean intensity. Data are means 6 SD of three independent experiments.
**, P,0.01. (F) Alexa Fluor 488 labeled ALD-DNA (AF488-ALD-DNA) was incubated with or without the purified SAP protein for 2 h (SAP plus ALD-
DNA). BMDMs were treated with or without chloroquine (100 mg/ml) before DNA incubation. The intracellular Alexa Fluor 488 labeled ALD-DNA
(AF488-ALD-DNA) in chloroquine-treated or untreated macrophages was determined by flow cytometry. Data are representative of results obtained
in three independent experiments. (G) The purified SAP protein was incubated with ALD-DNA (SAP plus ALD-DNA) for 2 h. RAW264.7 cells were
treated with PBS, ALD-DNA, or SAP plus ALD-DNA. 12 h later, levels of TNF-a, IL-1b, IL-6, IL-10, IL-12, and MCP-1 in the RAW264.7 cells were measured
by real-time PCR. Data are means 6 SD of three independent experiments. * P,0.05; ***, P,0.001.
doi:10.1371/journal.pone.0022659.g003
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linked genes co-deficency may confuse the elucidation of the role
of SAP in autoimmunity [22]. Therefore, study of SLE
pathogenesis in regarding to SAP in a mouse model with clear
genetic background is very critical and should be a prerequisite.
Herein, we use ALD-DNA-induced SLE murine model to
extensively study the role of SAP in SLE pathogenesis. In this
study, it was found that the ratios of SAP to DNA significantly
decreased in ALD-DNA-induced lupus mice as compared to
controls. SAP plasmid (pSAP) treatment in vivo could significantly
increase the levels of serum SAP and notably decreased the levels
of circulating DNA, thus simultaneously increasing the ratios of
Figure 4. pSAP administration in the early stage of SLE disease reverses ALD-DNA-induced lupus nephritis. BALB/c mice were
immunized subcutaneously with ALD-DNA (50 mg/mouse) or PBS for total 3 times in 4 weeks. Mice immunized with ALD-DNA were administrated
intramuscularly with pSAP (100 mg/mice) from week 4 after initial immunization (with the onset of proteinuria) and injected every 2 weeks for total 5
times. (A) The dynamics of SAP level in serum of lupus mice injected with pSAP (ALD-DNA plus pSAP) or pcDNA3 (ALD-DNA plus pcDNA3) were
determined by ELISA assay every 2 weeks. (B) The dynamics of circulating DNA level in serum of lupus mice injected with pSAP (ALD-DNA plus pSAP)
or pcDNA3 (ALD-DNA plus pcDNA3) were determined by ELISA assay every 2 weeks. (C) The ratios of SAP to DNA in SLE murine model injected with
pSAP (ALD-DNA plus pSAP) or pcDNA3 (ALD-DNA plus pcDNA3) at week 12 after initial immunization. Data are means 6 SD from 10 mice in each
group. ***, P,0.001. (D) Serum anti-dsDNA IgG levels of the mice were measured by ELISA assay every 2 weeks. (E) Anti-dsDNA IgG antibody titers in
serum of pSAP-treated lupus mice (ALD-DNA plus pSAP) or pcDNA3-treated lupus mice (ALD-DNA plus pcDNA3) were detected by ELISA assay at
week 8 after the initial ALD-DNA immunization. n=10. (F) Urine protein levels of the mice were assessed by BCA Protein Assay Kit (Thermo Fisher
Scientific) every 2 weeks. n=10. (G) The deposition of IgG-containing IC in glomeruli at week 12 after initial immunization. Imagines (6200) are
representative of at least 10 mice in each group. (H) Mean glomerular fluorescence intensity (arbitrary units) was determined for IgG in ALD-DNA-
immunized lupus mice and control mice at week 12 after initial immunization. n=10. **, P,0.01. (I) 12 weeks after initial immunization, nephritic
pathological changes were shown by H&E staining of renal tissues surgical resected from the mice. Imagines (6200) are representative of at least 10
mice in each group. (J) The kidney score was assessed using paraffin sections stained with H&E. n=10. ***, P,0.001.
doi:10.1371/journal.pone.0022659.g004
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22659Figure 5. pSAP administration in the late stage of SLE disease ameliorates ALD-DNA-induced lupus nephritis. BALB/c mice were
immunized subcutaneously with ALD-DNA (50 mg/mouse) or PBS for total 3 times in 4 weeks. Mice were administrated intramuscularly with pSAP
(100 mg/mice) from week 8 after initial immunization (when sever lupus nephritis has been established) and injected every 2 weeks for total 4 times.
(A) The dynamics of SAP level in serum of lupus mice injected with pSAP (ALD-DNA plus pSAP) or pcDNA3 (ALD-DNA plus pcDNA3) were determined
by ELISA assay every 2 weeks. (B) The dynamics of circulating DNA level in serum of lupus mice injected with pSAP (ALD-DNA plus pSAP) or pcDNA3
(ALD-DNA plus pcDNA3) were determined by ELISA assay every 2 weeks. (C) The ratios of SAP to DNA in SLE murine model injected with pSAP (ALD-
DNA plus pSAP) or pcDNA3 (ALD-DNA plus pcDNA3) at week 12 after initial immunization. Data are means 6 SD from 10 mice in each group. ***,
P,0.001. (D) Serum anti-dsDNA IgG levels were measured by ELISA assay every 2 weeks. (E) Anti-dsDNA IgG antibody titers in serum of pSAP-treated
lupus mice (ALD-DNA plus pSAP) or pcDNA3-treated lupus mice (ALD-DNA plus pcDNA3) were detected by ELISA assay at week 14 after the initial
ALD-DNA immunization. n=10. (F) Urine protein levels of the mice were assessed by BCA Protein Assay Kit (Thermo Fisher Scientific) every 2 weeks.
n=10. (G) The deposition of IgG-containing IC in glomeruli at week 12 after initial immunization. Imagines (6200) are representative of at least 10
mice in each group. (H) Mean glomerular fluorescence intensity (arbitrary units) was determined for IgG in ALD-DNA-immunized lupus mice and
control mice at week 12 after initial immunization. n=10. NS, not significant. (I) 12 weeks after initial immunization, nephritic pathological changes
were shown by H&E staining of renal tissues surgical resected from the mice. Imagines (6200) are representative of at least 10 mice in each group. (J)
The kidney score was assessed using paraffin sections stained with H&E. n=10. ***, P,0.001.
doi:10.1371/journal.pone.0022659.g005
Figure 6. pSAP administration in the late stage of SLE disease reduces inflammation in kidneys of mice. BALB/c mice were immunized
subcutaneously with ALD-DNA (50 mg/mouse) for total 3 times in 4 weeks. Mice were administrated intramuscularly with pSAP (100 mg/mice) from week 8
after initial immunizationandinjected every 2weeks for total 4 times. (A) 12weeks after initial immunization, the infiltration of leukocyte populationsinkidneys




+ cells were found in kidneys of pSAP-treated lupus
mice. Dataarerepresentativeof resultsobtainedinthree independentexperiments. n=10. (B) Atweek12, the kidneytissues were collected and homogenized,
the expression of TNF-a,I L - 1 b, IL-6, IL-10, IL-12, and MCP-1 were determined by ELISA assay. Data are means 6 SD of three independent experiments. n=8. **
P,0.01, *** P,0.001. (C) At week 12 after initial immunization, expression of TNF-a,I L - 1 b, IL-6, IL-10, IL-12, and MCP-1 in serum of the mice were determined by
ELISA assay. Data are means 6 SD of three independent experiments. n=8. * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0022659.g006
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insufficient in ALD-DNA-induced SLE mice, which further
provide the evidence that SAP defect rather than the deficiency
of SAP linked genes might contribute to the pathogenesis of
antinuclear autoimmunity in SAP
2/2 mice [15,20–22]. Notably,
the ratios of SAP to DNA were negatively correlated with the titers
of anti-dsDNA antibodies in lupus mice, which verified the critical
role of SAP insufficiency in ALD-DNA-induced autoimmunity,
although we did not exclude other factors contributing to the
pathogenesis of the SLE disease [23,24]. As SAP and IgG shared
the same binding site on FccR and competed for FccR binding,
SAP could be used to inhibit antibody or immune complex-
mediated immune response [11]. All these results strongly support
a role for SAP in the protection against self-DNA-induced
autoimmunity.
We thus adopted a gene therapy method using the pcDNA3-
SAP plasmid (pSAP) to treat lupus nephritis. The SAP protein
could be efficiently expressed and secreted into the culture
supernatants when pSAP was transfected into NIH3T3 cell line,
indicating that SAP cDNA cloned into pcDNA3 could be correctly
transcripted, translated and the protein was efficiently secreted in
vitro. Further study confirmed that the SAP protein could be
efficiently expressed and secreted into the systemic circulation via
intramuscular injection of pSAP, and SAP protein purified from
pSAP-treated mice could promote self-DNA clearance via binding
to self-DNA, indicating that efficiently expressed SAP protein
could perform the biological functions. Analysis of cytokine levels
of macrophages cultured with the complexes of SAP and DNA
revealed that levels of inflammatory cytokines including TNF-a,
IL-1b, IL-6, IL-12, and MCP-1 were notably decreased in the
macrophages cultured with SAP plus ALD-DNA; however, level
of IL-10 was significantly increased in the macrophages cultured
with SAP plus ALD-DNA as compared with those of macrophages
cultured with ALD-DNA alone, indicating that SAP inhibited
ALD-DNA-mediated innate immune response in vitro. However,
the mechanism of how SAP promotes the clearance of ALD-DNA
needs to be further revealed. The protective effect of SAP had also
been noticed by other groups and testified that the interaction of
SAP with FccR is able to mediate phagocytosis of apoptotic cells,
as well as mediate protective immune response [12,25]. In our
study, injection of pSAP in the early stage of SLE disease with the
onset of proteinuria notably reversed lupus nephritis. The
beneficial effect of pSAP treatment was associated with its
inhibitory effect on ALD-DNA-induced anti-dsDNA antibody
production and immune complex deposition, which was consistent
with the findings from other groups that anti-dsDNA antibodies
promoted initiation of lupus nephritis [26]. Furthermore, injection
of pSAP at the late stage of SLE disease with the established lupus
nephritis remarkably reduced proteinuria and lupus nephritis,
while slowly decreased levels of anti-dsDNA antibodies and
immune complex deposition were noticed in these pSAP-treated
mice, indicating that the protective effect of SAP treatment in the
late stage of SLE disease was not exclusively attributable to the
decreased levels of anti-dsDNA autoantibodies.
SAP is the main acute-phase reactants in mice and its capacity
to bind with DNA has been identified for more than 20 years
[13,14,27,28]. However, recent emerging evidences indicate that
SAP also plays a critical role in modulating cytokine production in
inflammatory reactions [10,11]. The inflamed kidneys of patients
with SLE, NZB/W F1 mice, and ALD-DNA-induced lupus mice
contain many lymphocytes around glomeruli, blood vessels, and in
the interstitium [8,29–31]. Our study verified again that CD45
+
leucocytes were infiltrated into kidneys of ALD-DNA-induced
lupus mice. SAP treatment in the late stage of SLE disease
significantly decreased the numbers of CD45
+ leucocytes including
T cells, B cells, and macrophages but not dendritic cells in kidney
tissue of ALD-DNA-induced lupus mice and the underlying
mechanisms need to be elucidated in the future. Further analysis of
inflammatory markers revealed that SAP treatment notably
decreased systemic and local inflammatory cytokine levels of
TNF-a, IL-1b, IL-6, IL-12, and MCP-1, which were closely
associated with the severity of lupus nephritis [18]. However,
inhibitory cytokine IL-10 was notably increased in pSAP-treated
lupus mice, which might also partly contribute to the alleviation of
lupus nephritis. Our results were in good agreement with previous
studies, and further confirmed the immunomodulatory function
and potential protective and therapeutic effect of SAP in ALD-
DNA-induced lupus nephritis.
In conclusion, we showed that SAP gene administration at the
onset of proteinuria could reverse lupus nephritis. The main
mechanism seems to be associated with the effective inhibiting the
production of anti-dsDNA antibodies and immune complex
deposition. While SAP gene treatment in the stage of established
lupus nephritis could reduce the disease severity, which was
possibly attributable to the decreased infiltration of lymphocytes
and reduced levels of inflammatory markers beyond decreased
anti-dsDNA autoantibody production. Our findings may provide
an insight into better understanding of the underlying mechanism
of ALD-DNA-induced lupus nephritis, and provide the preclinical
data indicating that SAP administration can alleviate lupus
nephritis. This strategy may be a clinically relevant and feasible
therapeutic method for patients suffering from self-DNA-induced
nephritis or other autoimmune diseases which accompany with
decreased clearance of apoptotic cells.
Materials and Methods
Ethics statement
All experiments carried out in this study were strictly performed
in a manner to minimize suffering of laboratory mice. All animal
procedures were performed according to the Guide for the Care
and Use of Medical Laboratory Animals (Ministry of Health, P.R.
China, 1998) and with the ethical approval of the Shanghai
Medical Laboratory Animal Care and Use Committee (Permit
number: SYXK 2007-0036) as well as the Ethical Committee of
Fudan University (Permit number: 2007016).
Mice and plasmid
Six-week-old female BALB/c mice were purchased from the
Experimental Animal Center of Chinese Academy of Sciences
(Shanghai, P. R. China). Mice were housed in a specific pathogen-
free room under controlled temperature and humidity. The full
length of SAP cDNA was amplified from total RNA of murine
liver using the primers 59-CGA AGC TTG CCA CCA TGG
ACA AGC TGC TGC-39 and 59-CGG AAT TCC CTC TTA
CAC ATC GGC AAT C-39. 24 nucleotides encoding FLAG
epitope (DYKDDDDK) were added directly at the carboxyl-
terminal of SAP gene sequence by primer design. SAP cDNA with
a FLAG tag was inserted into the pcDNA3 vector (Invitrogen) to
generate pcDNA3-SAP plasmid (pSAP). The plasmid construct
was confirmed by DNA sequencing.
Generation of bone marrow-derived macrophages
(BMDMs)
Bone marrow (BM) cells were harvested from uninfected,
normal BALB/c mice and filtered through nylon mesh. BM cells
were cultured in L929 cell-conditioned medium at a density of
3610
5 cells/ml of medium and maintained in a 5% CO2
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initial BM cells culture, the medium was changed and the purity of
F4/80
+ cells was more than 90%, as determined by flow cytometry
(FACSCalibur; BD Biosciences).
DNA preparation
ALD-DNA and UnALD-DNA were prepared with murine
splenocytes which were generated from surgical resected spleens of
six- to eight-week-old female BALB/c mice and cultured with or
without Con A (Sigma-Aldrich) in vitro as previously described [7].
Briefly, for generation of ALD-DNA, splenocytes were seeded at
2610
6 cells/ml in 75 cm
2 cell culture flask and cultured in the
presence of Con A (5 mg/ml) for 6 days to induce apoptosis. The
apoptotic cells were stained with FITC-labeled Annexin V (BD
Biosciences) and propidium iodide (PI; Sigma-Aldrich), and sorted
using a FACSAria (BD Biosciences). Genomic DNAs from syngeneic
apoptotic splenocytes were treated with S1 nuclease (TaKaRa) and
proteinase K (Sigma-Aldrich), and then purified using the DNeasy
Blood & Tissue Kits (Qiagen) according to the manufacturer’s
instructions. UnALD-DNA was prepared with unactivated (resting)
splenocytes and extracted using the same methods. To exclude
contaminations with LPS, sterile endotoxin-free plastic ware and
reagents were used for DNA preparation. DNA samples were also
monitored for low level of endotoxin by the Limulus amoebocyte
lysate assay (BioWhittaker) according to the manufacturer’s instruc-
tions. The concentration of DNA was determined by detection of the
absorbance (A) at 260 nm. The apoptotic DNA ladder of ALD-DNA
was confirmed by agarose gel electrophoresis (AGE).
Generation of SLE murine model
To generate SLE murine model, 6- to 8-wk-old syngeneic
female BALB/c mice were divided into several groups of 8–10
mice and actively immunized by subcutaneous injection on the
back with 0.2 ml of an emulsion containing ALD-DNA (50 mg/
mouse) in phosphate-buffered saline (PBS) plus equal volume of
complete Freund’s adjuvant (CFA; Sigma-Aldrich) at week 0, and
followed by two booster immunizations of ALD-DNA (50 mg/
mouse) emulsified with IFA (Sigma-Aldrich) at week 2 and week 4
for total 3 times as previously described [6,7]. Eight to 10 mice in
each group received an equal volume of PBS plus CFA or IFA, or
UnALD-DNA (50 mg/mouse) plus CFA or IFA were used as
contols. Mice were bled from retro-orbital sinus prior to
immunization and at 2-week internals until 3 months after the
initial immunization. 8 or 12 weeks later, mice were sacrificed and
surgical resected spleens and kidneys were collected for further
cellular function and tissue histology analysis.
Autoantibody and proteinuria examination
Anti-dsDNA antibodies in the mice serum were determined by
ELISA assay as described previously [6]. In briefly, ELISA plates
(Costar) were pretreated with protamine sulphate (Sigma-Aldrich)
and then coated with calf thymus dsDNA (Sigma-Aldrich). After
incubation with mouse serum, the levels of anti-dsDNA Abs were
detected with the horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgG (Southern Biotech). Tetramethylbenzidine (TMB)
substrate was used to develop colors and absorbance at 450 nm was
measured on a microplate reader (BIO-TEK ELX800). Proteinuria
of the mice was measured with the BCA Protein Assay Kit (Thermo
Scientific) according to the manufacturer’s instructions.
Measurement of anti-dsDNA antibody titers
Anti-dsDNA antibody titers in the mice serum were determined
by ELISA assay as described previously [34]. In briefly, protamine
sulphate pre-treated 96-well microtitre plates (Costar) were coated
with calf thymus dsDNA (Sigma-Aldrich; 50 mg/ml) for 2 h at
37uC and then placed overnight at 4uC. After washing three times
with PBS containing 0.05% Tween-20 (PBST), the plates were
blocked with 1% BSA for 1 h, and serial dilutions of serum in
PBS–1% BSA were added for 1 h at 37uC. After washing, the
plates were incubated with 1:1000 dilution of horseradish
peroxidase (HRP)-conjugated goat anti-mouse IgG (Southern
Biotech) for 1 h at 37uC. Tetramethylbenzidine (TMB) substrate
was used to develop colors and absorbance at 450 nm was
measured on a microplate reader (BIO-TEK ELX800).
Measurement of SAP level
To assess protein levels of SAP in serum of mice or in the
culture supernatants, ELISA assays were performed with the
following anti-SAP Abs and SAP standards: sheep anti-mouse SAP
(Calbiochem), rabbit anti-mouse SAP (Calbiochem), and mouse
SAP (Calbiochem) as previously described [35].
Measurement of circulating DNA level
DNA was extracted from serum samples and then quantified
using a PicoGreen DNA detection kit (Invitrogen) according to the
manufacturer’s instructions [36]. In briefly, DNA was extracted
from 200 ml of serum samples using a QIAamp Blood Kit
(Qiagene) using the blood and body fluid protocol as recom-
mended by the manufacturer. After the removal of most proteins
by digestion with proteinase K, the sample was applied to the
QIAamp 96 plate. DNA was adsorbed onto the silica membrane
during a brief centrifugation step, while any remaining protein,
salt and other contaminants were completely removed by three
consecutive washes. Membrane-bound DNA was then eluted in
double deionized H2O or Tris–EDTA buffer. A final elution
volume of 200 ml was used. Quantification of DNA was carried out
using a PicoGreen DNA detection kit (Invitrogen). Calf thymus
DNA (100 mg/ml; Sigma-Aldrich) was used as the standard. The
concentration of DNA in the standard curve ranged from 0 to
100 ng/ml. Briefly, 20 ml of final DNA eluated was mixed with
1 ml of Tris–EDTA (10 mmol/l Tris–HCl, 1 mmol/l EDTA,
pH 7.5) diluted with PicoGreen reagent. Fluorescence intensity
was measured on an F-2000 spectrofluorometer (Molecular
Devices) at excitation wavelength of 480 nm and an emission of
520 nm. Standard curve used to determine the levels of circulating
DNA in the samples was established by the linear relationship
between the known concentrations of calf thymus DNA (Sigma-
Aldrich) and the corresponding fluorescence intensities.
Immunohistochemistry examination
The expression of SAP protein in the muscle tissue received
pcDNA3-SAP (pSAP) injection was analyzed by immunohisto-
chemistry. In briefly, mice were injected with pSAP (100 mg/mice)
at the site of femoral muscle. 3 days later, the muscle tissue
harvested from pSAP treated mice were fixed in 4% paraformal-
dehyde, processed on a standard histology processor, embedded in
paraffin, and cut into 5 micron sections. Paraffin sections were
dewaxed in xylene and rehydrated in decreasing concentrations of
alcohol. Sections were exposed to citrate buffer and heat antigen
retrieval and then blocked and incubated with rabbit anti-mouse
SAP antibody (Calbiochem). Sections were subsequently assayed
with the Super Sensitive Polymer-HRP IHC Detection System
(Vector Laboratories) according to the manufacturer’s instructions.
3, 39-Diaminobenzidine (DAB) substrate (Dako) was used to
develop slides. Slides were counterstained with hematoxylin (Dako)
and coverslipped using Permount mounting media (Fisher
Scientific). Pictures were acquired with a 206/0.45 Plan Fluor
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equipped with ACT-1 software (Nikon). Original magnification
was 4006.
Western blot analysis
Six-week-old female BALB/c mice were injected intramuscu-
larly with pSAP (100 mg/mice). 10 days later, the serum was
collected and western blot analysis was performed as described
previously [37]. In briefly, serum was electrophoresed on SDS-
PAGE gels and then transferred to the PVDF membrane. The
membrane was probed with rabbit anti-SAP (Calbiochem), mouse
anti-FLAG (Santa Cruz), or rabbit anti-GAPDH antibody (Santa
Cruz), followed by HRP-conjugated goat anti-rabbit antibody
(Santa Cruz) or goat anti-mouse antibody (Southern Biotech). The
signals were developed by chemiluminescence (Pierce).
Binding ability of SAP to DNA
The binding ability of SAP to DNA was detected by dot blot
analysis with mouse SAP protein purified from pSAP treated mice
and rabbit anti-mouse SAP (Calbiochem) as previously described
[38]. In briefly, DNA (1 mg) was spotted on the nitrocellulose
membranes. After the incubation of SAP protein (1 mg/ml), anti-
SAP Abs, and peroxidase-labeled IgG Abs (Southern Biotech), the
blots were developed with 3, 39-Diaminobenzidine (DAB) to
measure the binding ability of SAP to DNA. Quantitative analysis
of blots was done using Mini-Transilluminator (Bio-Rad) equipped
with molecular analysis software. The binding ability of SAP to
DNA was reflected as mean intensity.
DNA uptake in vitro
ALD-DNA was labeled with Alexa Fluor 488 (Invitrogen)
according to the manufacturer’s instructions. The labeled ALD-
DNA (referred as AF488-ALD-DNA) was purified using Bio-Rad
Micro Bio-Spin P-30 column (Bio-Rad, Hercules, CA) according to
themanufacturer’s protocol.AF488-ALD-DNAwasincubatedwith
purified mouse SAP protein (SAP plus ALD-DNA) at 37uC for 2 h.
BMDMs were treated with chloroquine (100 mg/ml) before DNA
incubation. The intracellular Alexa Fluor 488 labeled ALD-DNA
(AF488-ALD-DNA) was determined by flow cytometry (FACSCa-
libur) as previously described [39]. All flow cytometry data were
acquired on a BD FACSCalibur (BD Biosciences) in CellQuest (BD
Biosciences) and analyzed by FlowJo software (Tree Star).
Real-time PCR analysis
Total RNA was isolated from cultured cells with TRIzol reagent
(Invitrogen) and was reverse-transcribed (RT) using a cDNA
synthesis kit (MBI Ferments) according to the manufacturer’s
instructions. Subsequently, cDNA was subjected to quantitative
real-time PCR using a Lightcycler480 and SYBR Green system
(Roche Diagnostics) following the manufacturer’s protocol [40].
Flow cytometry analysis
Murine renal tissues were surgical resected and dispersed in
RPMI 1640 contained 5% FBS and 0.1% collagenase (Sigma-
Aldrich) at 37uC for 30 min, followed by progressive sieving to
obtain single-cell suspensions. To assess the infiltration of leucocyte
populations in kidneys of mice, flow cytometry analysis were
performed with PE-labeled anti-CD45, PerCP-labeled anti-CD4,
FITC-labeled anti-CD19, and FITC-labeled anti-F4/80 (BD
Biosciences). All flow cytometry data were acquired on a BD
FACSCalibur (BD Biosciences) in CellQuest (BD Biosciences) and
analyzed by FlowJo software (Tree Star).
ELISA Assay
To assess protein levels of TNF-a, IL-1b, IL-6, IL-10, IL-12,
and MCP-1 in the homogenized kidney tissue and in serum of
mice, ELISA assays were performed with relative ELISA Kits
(eBioscience) according to the manufacturer’s instructions.
Pathological analysis
For histology analysis, murine renal tissues were surgical resected
and fixed in 4% paraformaldehyde (Sigma-Aldrich), processed, and
embedded in paraffin. H&E staining of renal tissue sections were
performed according to the manufacturer’s instructions and
assessed by a pathologist blinded to treatment group. The kidney
score of glomerulonephritis was determined by using the ISN/
RPS2003 classification. Fluorescent staining of cryosections was
used for autoantibody deposition analysis in the glomeruli. Sections
were fixed in acetone for 10 min and incubated with FITC-
conjugated goat anti-mouse IgG (H+L chain specific) Ab (Sigma-
Aldrich) for 30 min. Pictures were acquired with Nikon SCLIPSS
TE2000-S microscope (Nikon) equipped with ACT-1 software
(Nikon). Original magnification was 6200.
Statistical analysis
All data are expressed as means 6 SD of three independent
experiments or from a representative experiment of three
independent experiments. The statistical significance of the
differences in the experimental data was valued by the Student’s
t-test. The statistical significance level was set as * P,0.05,
** P,0.01, *** P,0.001.
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